Company Announcements

Epigenetic tools firm Cambridge Epigenetix closed a $21 million Series B financing in March, led by Google Ventures, and appointed Dr. Geoff Smith as CEO. Most recently, he served as site lead and vice president of Product Development at Illumina.

Genovis announced a strategic cooperation agreement with CRO Alphalyse in which they will provide their respective enzymes for antibodies and MS expertise.

Bioengineering solutions provider DNA2.0 opened a European office in March in Basel, Switzerland.

In March, Emulate secured $28 million of its Series B financing to fund development of a Human Emulation System, an automated product suite that includes Organ-Chips, instrumentation hardware and software.

Biotech firm Forge Therapeutics and Active Motif are collaborating on epigenetic research and drug discovery.

GTCR made a strategic equity investment in life science product firm Vector Laboratories through its Maravai LifeSciences management partnership.

In April, Persomics, which supplies ImagineArrays for phenotypic screening, announced an exclusive license agreement with Whitehead Institute, making it the sole rights holder to a reverse transfection method.

Product Introductions

In March, Agilent Technologies and Eurofins Genomics announced a collaboration to offer Agilent custom components and an assembled plasmid service for Agilent’s SureVector next generation cloning kits.

InSphero launched the 3D InSight Multi-donor Human Liver Microtissues for prediction of drug-induced liver injury. It is comprised of pooled hepatocytes from multiple donors.

Diagenode launched ChIP-seq and reduced representation bisulfite sequencing services.

Horizon Discovery released HDx FFPE RNA Fusion Reference Standards, independent analytical controls for the optimization and validation of targeted RNA-seq, end point RT PCR or RT qPCR assays.

AMSBIO launched a range of primary human cancer cells obtained directly from a variety of tumor types.

DiscoverX introduced the KLIR Retroparticles product line, providing complete flexibility to develop a simple cytotoxicity assay in almost any cell line.

In April, ALPCO introduced the STELLUX Chemi Human IL-6 ELISA, the first cytokine assay in the STELLUX Chemiluminescence product line.

Abcam launched a suite of immunoassay products based on its recombinant, monoclonal antibody pairs. The stand-alone match antibody-pair kits enable scale up.

Cell Signaling Technology launched four new monoclonal antibodies relevant to immuno-metabolism and tumor immunology, which are recommended for IHC.